| Literature DB >> 32893182 |
Leonie T Jonker1, Maarten M H Lahr2, Suzanne Festen3, Maaike H M Oonk4, Geertruida H de Bock2, Barbara L van Leeuwen5.
Abstract
OBJECTIVES: Although the increasing cancer incidence in older patients is widely recognised, older patients remain underrepresented in clinical cancer trials and eHealth studies. The aim of this research is to identify technological and patient-related barriers to inclusion of this population in a clinical eHealth study.Entities:
Keywords: Aged; Cancer; Digital health literacy; Postoperative care; Preventive health services; Surgical oncology; Telemedicine; eHealth
Mesh:
Year: 2020 PMID: 32893182 PMCID: PMC7472980 DOI: 10.1016/j.jgo.2020.08.008
Source DB: PubMed Journal: J Geriatr Oncol ISSN: 1879-4068 Impact factor: 3.599
Fig. 1Study flowchart.
Patient and tumour characteristics.
| Variables | Participants | Non-Participants | |
|---|---|---|---|
| General patient characteristics | |||
| 72.8 (5.4) | 75.1 (5.7) | 0.01* | |
| Male | 42 (64.6) | 31 (36.0) | |
| Female | 23 (35.4) | 55 (64.0) | 0.00* |
| Dutch | 64 (98.5) | 81 (94.2) | 0.24 |
| | |||
| ASA 1–2 | 53 (81.5) | 49 (57.0) | |
| ASA 3–4 | 12 (18.5) | 37 (43.0) | 0.00* |
| | 4.0 (2.0–6.0) | 3.0 (2.0–6.0) | 0.88 |
| | 28 (43.1) | 58 (67.4) | 0.00* |
| | 26.9 (4.2) | 28.0 (6.0) | 0.18 |
| | |||
| Married | 53 (81.5) | 50 (58.1) | |
| Widow(er) | 9 (13.9) | 24 (27.9) | |
| Divorced | 1 (1.5) | 5 (5.8) | |
| Single | 2 (3.1) | 7 (8.1) | 0.01* |
| | |||
| Independent, alone | 12 (18.8) | 33 (38.4) | |
| Independent, with others | 52 (81.3) | 51 (59.3) | |
| Nursing home | 0 | 2 (2.3) | 0.02* |
| Concerns about hospital admission, | 17 (27.9) | 27 (34.2) | 0.47 |
| Anxiety that influences daily life, | 4 (6.6) | 4 (5.1) | 0.73 |
| Use of psychiatric medication? | 6 (9.8) | 8 (10.3) | 1.00 |
| | 4 (6.2) | 14 (16.7) | 0.05 |
| | 34 (52.3) | 39 (45.3) | 0.42 |
| Intracavitary | 54 (83.1) | 64 (74.4) | |
| Superficial | 11 (16.9) | 22 (25.6) | 0.20 |
| Gastro-intestinal oncology | 48 (73.8) | 53 (61.6) | |
| Gynaecological oncology | 7 (10.8) | 19 (22.1) | |
| Other oncology | 10 (15.4) | 14 (16.3) | 0.17 |
| 18 (27.7) | 35 (40.7) | 0.12 | |
| 24 (36.9) | 36 (41.9) | 0.54 | |
SD: standard deviation; ASA: American Society of Anesthesiologists [19]; BMI: body mass index; ADL: activities of daily living; ⁎Statistically significant, p < 0.05.
Data missing for four participants and seven non-participants.
Data missing for four participants and eight non-participants.
Data missing for two non-participants.
Mostly colorectal cancer (n = 77).
Vulva carcinoma (n = 20) and ovarium carcinoma (n = 6).
Mostly sarcoma (n = 12).
Number of participants and non-participants with postoperative adverse outcomes, in total and per type of surgery.
| Participants | Non-participants | ||
|---|---|---|---|
| Surgery performed | |||
| As planned | 60 (98.4) | 77 (96.3) | |
| Irresectable tumour | 1 (1.6) | 3 (3.7) | 0.63 |
Gastro-intestinal oncological surgery | 44 (72.1) | 48 (60.0) | |
Gynaecological oncological surgery | 7 (11.5) | 19 (23.8) | |
Other oncological surgery | 10 (16.4) | 13 (16.3) | 0.17 |
Gastro-intestinal | 12 (27.3) | 21 (43.8) | 0.13 |
Gynaecological | 0 | 2 (10.5) | 1.00 |
Other | 1 (10.0) | 1 (7.7) | 1.00 |
Gastro-intestinal | 13.0 (7.0–22.0) | 15.0 (9.0–20.0) | 0.30 |
Gynaecological | 2.0 (2.0–3.0) | 2.0 (2.0–5.0) | 0.50 |
Other | 4.0 (2.5–13.0) | 6.0 (4.0–10.5) | 0.24 |
Gastro-intestinal | 16 (36.4) | 25 (52.1) | 0.13 |
Gynaecological | 0 | 1 (5.3) | 1.00 |
Other | 3 (30.0) | 2 (15.4) | 0.62 |
Gastro-intestinal | 1 (2.3) | 1 (2.1) | 1.00 |
Gynaecological | 0 | 0 | – |
Other | 1 (10.0) | 0 | 0.44 |
| Referral | |||
Gastro-intestinal | 0 | 6 (12.8) | 0.03* |
Gynaecological | 0 | 4 (21.1) | 0.55 |
Other | 0 | 2 (15.4) | 0.50 |
Gastro-intestinal | 7 (16.3) | 11 (23.4) | 0.40 |
Gynaecological | 1 (14.3) | 1 (5.3) | 0.47 |
Other | 4 (44.4) | 5 (38.5) | 1.00 |
Gastro-intestinal | 5 (11.6) | 13 (27.7) | 0.06 |
Gynaecological | 0 | 1 (5.3) | 1.00 |
Other | 4 (44.4) | 4 (30.8) | 0.66 |
ICU: intensive care unit; IQR: interquartile range; ⁎Statistically significant, p < 0.05.
Complications classified as Clavien–Dindo 2 or higher.
Complications and unplanned readmissions within 30 days post-discharge.
Fig. 2Survival analyses of non-participants and participants.